CORDIS
EU research results

CORDIS

English EN
Prevention of Liver Fibrosis and Cancer in Africa

Prevention of Liver Fibrosis and Cancer in Africa

Objective

Chronic hepatitis B virus (HBV) infection affects 350 million people worldwide and 25-30% of these individuals will die as a result of their infection mainly as a results of hepatocellular carcinoma HCC. Liver cirrhosis, high viral load and dietary exposure to aflatoxin are recognised as risk factors for hepatocellular carcinoma amongst HBV carriers. However, these variables do not account for all cases of HCC and decompensated cirrhosis is rarely ever seen in West Africa suggesting that advanced liver fibrosis may not be an important risk factor in this population. A large case control study on HCC will be used to evaluate the importance of liver fibrosis and other established risk factors in West Africa and to explore other potential oncogenic determinants. The case-control study will generate serum, urine and DNA samples for proteomic, metabonomic and genomic analysis to identify biomarkers and aetiological agents for HCC.
Effective treatment for HBV infection is now available in the developed world but treatment programmes have not been developed for resource poor settings even though some of the effective medication is now available at low cost for HIV management. A trial of HBV treatment in a group of carefully selected high risk patients will be conducted to demonstrate that the incidence of HCC can be reduced in this population as has been observed in Asian patients. The treatment trial will also be used to evaluate the efficacy of screening by ultrasound for early tumours which can be treated with percutaneous alcohol injection.
This comprehensive programme therefore aims to reveal novel aetiological factors for HCC, identify and evaluate biomarkers and demonstrate the efficacy of selective antiviral therapy to prevent HCC

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Address

South Kensington Campus Exhibition Road
Sw7 2az London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 642 000

Administrative Contact

Tatjana Palalic (Ms.)

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDICAL RESEARCH COUNCIL

United Kingdom

EU Contribution

€ 1 105 300

CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER

France

EU Contribution

€ 236 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 158 000

JOS UNIVERSITY TEACHING HOSPITAL

Nigeria

EU Contribution

€ 189 500

UNIVERSITE CHEIKH ANTA DIOP DE DAKAR

Senegal

EU Contribution

€ 324 000

Ministry of Health and Social Welfare

The Gambia

EU Contribution

€ 137 200

XEPTAGEN SPA

Italy

EU Contribution

€ 208 000

Project information

Grant agreement ID: 265994

Status

Closed project

  • Start date

    1 February 2011

  • End date

    31 January 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 781 843,40

  • EU contribution

    € 3 000 000

Coordinated by:

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom